Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
222 participants
Study Classification
OBSERVATIONAL
Study Start Date
2019-05-01
Study Completion Date
2022-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In 2014, the Joint United Nations Program on HIV/AIDS (UNAIDS) issued treatment goals for Human Immunodeficiency Virus (HIV), the 90-90-90 target. It is important to track success results at each stage of the HIV continuum of care to evaluate progress towards the 90-90-90 target. Although ART can suppress HIV-1 infection to undetectable levels of plasma viremia, HIV DNA integrate and persist in resting CD4+ T cells. Most of the HIV DNA in these cells is defective and cannot cause infection. However, latent HIV-1 genomes that encode replication-competent virus can resurface once ART is discontinued. This latent reservoir is believed to be the largest impediment to a cure by ART alone. There is need for expansion of research examining HIV latency in the context of sustained viral suppression with an eye towards developing a possible cure regimen that could be used on a large scale. To date, there have been no systematic studies to quantify the latent reservoir in virally suppressed HIV-infected patients in Africa. Detecting how much of the inducible virus is left in the human body after ART poses the greatest challenge to fully curing HIV. This study is designed to enroll 222 virally suppressed HIV infected men and women, who will be prospectively followed to document antiviral cocktail, viral suppression and incidences of rebound, measure the size of the latent HIV reservoir and examine the immunological correlates of the latent reservoir. Data generated through this study will provide a clear framework for high-burden countries to reduce gaps at each stage of the HIV continuum of care, maximize linkage, retention and health outcomes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants
NCT00980538
HIV Infections
HIV-1
ACTIVE_NOT_RECRUITING
PHASE3
Evaluation of Innovative Combinatorial stratégies of Anti-latency and Anti-immune Activation Drugs Targeting HIV Reservoir
NCT04741100
HIV
WITHDRAWN
Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV
NCT05215704
HIV Infections
HIV-1-infection
HIV-2 Infection
RECRUITING
Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults
NCT00051831
HIV Infections
COMPLETED
NA
Evaluating the Effect of CHanging EnfuvirtidE to Raltegravir in HIV Infected Subjects
NCT00529243
HIV Infections
COMPLETED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background: Based on the 2013 Kenya AIDS Indicator Survey, 58% of people living with HIV/AIDS (PLWHA) aged 15-64 years in Kenya were eligible for Antiretroviral Therapy (ART), but only 63% of them were found to have been initiated. Previous studies have shown that an estimated 33% to 40% of patients are expected to fail treatment in the first 12 months of second-line ART. In many low and middle income countries (LMIC) with no third-line regimens available, second-line ART is the last option for patients hence failure greatly impacts patients management. A study in Kenyan national ART program suggests that about 27% of patients with second-line failure are in need of a switch to third-line therapy, with 25% demonstrating complete exhaustion of alternative first and second-line regimens. Although new drugs for HIV treatment are being developed, HIV treatment options within national programmes remain limited. Therefore, the durability of switch to second-line regimens as well as durability to second-line regimens is critical for the long-term success of ART and ultimately patient survival. Fortunately, virological (VL) failure on second-line ART does not necessarily warrant a switch to a third-line regimen, as Protease Inhibitors (PIs) have a high genetic barrier to resistance mutations, particularly among PI naïve patients. As failure on second-line ART is more related to suboptimal adherence than drug resistance, the management of VL failure on second-line typically involves intensified adherence counselling with drug substitutions recommended in cases of documented resistance mutations, severe adverse drug reactions (ADR) or drug interactions. While rates of drug substitutions and the durability of first-line ART have been previously described, there is very little information on patterns of drug substitutions for patients on second-line ART across ART national guideline-specific periods. Additionally, little is known about the impact of ART guideline changes on the durability of second-line ART and continuity of care.
While determining the durability of ART is critical in terms of monitoring success and possible ART mutations, the desired outcome is eradication of HIV by 2030.The concept of eradication of the HIV from infected patients has therefore gained much attention in the last few years. ART has changed the dynamic of the HIV epidemic through suppression of HIV-1 RNA to undetectable plasma levels. As a sign of the seriousness of countries to achieve 90-90-90, it is important to track success results at each stage of the HIV continuum of care and most importantly the viral suppression. Although antiretroviral therapy can suppress HIV-1 infection to undetectable levels of plasma viremia, HIV DNA integrate and persist in resting CD4+ T cells. Latent HIV infection of CD4+ T cells, established during the early stages of infection, necessitates lifelong ART, and treatment failure can lead to the selection of drug resistance mutations in the viral genome, which may be archived in the cellular reservoir. Most of the HIV DNA in these cells is defective and cannot cause infection. However, latent HIV-1 genomes that encode replication- competent virus can resurface once ART is discontinued. This latent reservoir having replication- competent virus has a long half-life, and is believed to be the largest impediment to a cure by ART alone. This justifies expansion of research examining HIV latency in the context of sustained viral suppression with an eye towards developing a possible cure regimen that could be used on a large scale. Recently, pharmaceutical approaches have focused on the development of molecules able to reactivate HIV from latently infected cells in order to render them susceptible to combined antiretroviral therapy (c-ART), viral cytopathic effects and host immune responses. Obviously, exposing latent virus and killing it with ART rests on an assumption that the activated virus will be susceptible to the ART a person takes. As such, it is important to discern whether reactivated HIV proviruses are susceptible to the ART regimen for maximum benefit to the patient.
The vast majority of HIV-infected individuals currently live in sub-Saharan Africa where fully suppressive ART is expanding rapidly. Due to this expansion, a large number of patients are expected to achieve full viral suppression. There is need therefore to quantify and document the size of latent HIV reservoir in virally suppressed patients in this region for individualized treatment. To date, there have been no systematic studies to quantify the latent reservoir in virally suppressed HIV-infected patients in Africa. Detecting how much of the inducible virus is left in the human body after antiretroviral therapy poses the greatest challenge to fully curing HIV. Stratifying virally suppressed patients base on the quantity of latent HIV, ART regimens and immune status may inform eligible candidates for latency reactivation care when one comes available.
Hypothesis: Archived proviruses in the latent reservoir are sustained in aviremic patients and are an impediment to HIV cure.
General Objective: Investigate the impact of inducible, replication-competent latent HIV-1 as an impediment to HIV/AIDS cure.
Objectives:
* Document treatment cocktail and determine the rate of viral rebound in aviremic patients; As a sign of the seriousness of countries to achieve 90-90-90, it is important to track success results at each stage of the HIV continuum of care. The investigator will conduct three analyses on patients: 1) Document antiviral cocktail; 2) Duration of viral suppression; 3) Monitor incidences of viral rebound. This will provide a clear framework for using data to maximize linkage, retention and health outcomes. It will also help high-burden countries to use this data at a sub-national and county level to improve service linkage and reduce gaps at each stage of the HIV continuum of care.
* Examine and measure the size of latent HIV reservoirs in virally suppressed patients; Once a patient achieves viral suppression with antiretroviral therapy, it becomes very important to tell how much virus is still left, and whether it can replicate. Such data may lead to an understanding of HIV pathogenesis and to adjust the therapy to improve the quality of life of the HIV patient and inform HIV-1 eradication strategies. This data will enable to identify patients who will be eligible candidates for cure treatment when one comes available.
* Explore the level of immune activation in virally suppressed HIV-infected patients in correlation with the size of the reservoir; In addition to harboring HIV-1 in a long-lived reservoir, individuals on ART have persistently elevated levels of inflammation and T cell activation. Abnormal inflammation and immune activation may contribute to HIV-1 persistence by driving proliferation and activation of HIV-1-infected cells and by activating uninfected cells that can support low-level viral replication. The investigator propose to evaluate sizes of HIV-1 reservoir in relation to inflammation and T cell activation in HIV-1 in aviremic patients on therapy to inform strategies aimed at reducing HIV-1 reservoirs, inflammation and activation that persist despite ART.
Study population: The study will utilize HIV-1 infected patients (18 to 70 years) attending HIV care and treatment facilities in three counties of Meru, Kilifi, and Mombasa. Analysis of medical records to document ART cocktail will be performed. Latent HIV will be determined in patients with viral suppression, defined according to WHO guideline 2016, and followed for 24 months to monitor incidences of viral rebound. A viral load threshold of \<1000 copies/mL defines treatment success according to the 2016 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Hence subjects with viral load test results below the threshold will be considered as having suppressed viral loads and included in the study. Subjects with complete suppression ( with viral loads below the limit of detection) will also be included in the study.
Study sites: Participants (222) will be recruited from Tudor District Hospital in Mombasa, Malindi District Hospital in Kilifi, Maua Methodist Hospital and Meru Level Five Hospital in Meru Counties of Kenya. Sites were selected depending on volumes of HIV infected individuals registered in the HIV comprehensive care centers who have been taking HAART for at least the last 12 months and have shown virus suppression in at least one of the previous viral load test result.
Sample size calculation: Hospitals will be purposively sampled from each of the three counties of Meru, Kilifi and Mombasa due to the high HIV burden in those counties. Using the reported HIV estimated prevalence in each of the three counties, the sample size will be calculated for each county using the following formula by Armitage. Hence, sample size for;
1. Mombasa County will be; 107 HIV infected individuals
2. Meru County will be; 43 HIV infected individuals
3. Kilifi County will be; 52 HIV infected individuals
Therefore, a minimum sample size of 202 HIV infected individuals will be required for this study. However, to account for potential non-response, non-compliance, and lost to follow-up cases, 10% of the minimum sample size per county will be added hence 222 HIV infected individuals in all the three counties will be utilized.
Ethical consideration: Before commencement of the study, approval will be sought from the Centre for Microbiology Research -KEMRI, Centre Scientific Committee (CSC) as well as the KEMRI Scientific and Ethical Review Unit (SERU). Once the approval is obtained from KEMRI, The investigator will pursue approval for the study from the respective county Director of medical services where the study will be carried out. Thereafter approval from the sites (hospitals) will be sought before commencement of the study. Informed consent will be obtained from adult participants. Recruitment will be voluntary and volunteers will be encouraged to ask questions concerning their rights. Study participants who, during the course of the study are in any way incapacitated will have their consent sought afresh. Participants will not incur any costs as a result of participating in the study and will be free to withdraw from the study whenever they so wish. A coded identification number will be assigned to each participant and used only for the purposes of sample tracking. Documents linking personal identifiers and specimen results will be destroyed after the study. All information will be kept confidential.
Data collection and laboratory methods: Participant sociodemographic data, ART regimen, CD4+ cell count, opportunistic infections, World Health Organization (WHO) staging, and physician-reported adherence will be retrospectively collected from patient folders. All participants will undergo plasma HIV-1 RNA and CD4 quantification at enrollment and after every 6 months during follow up. Baseline viral load and CD4+ cell counts will be closest to ART regimen start. All HIV-1 RNA levels obtained as part of the study, will be made immediately available to the respective physician. The investigator will evaluate every paired HIV-1 viral load (VL) and CD4 count performed to analyze the durability of viral suppression and the risk of rebound among patients with virologic suppression. Time to rebound will be computed using consecutive sequences of observations for subjects whose initial two viral loads will be below the lower limit of quantification and had a viral load measurement within the duration of follow up days.
Statistical analyses: A ratio paired test or equal variance two-sample t-test will be used to calculate the significance while comparing sets of data whenever necessary. All statistical analysis will be performed using PRISM software. A P value of less or equal to 0.05 will be considered to be significant in each of the statistical analyses performed. Correlations between two independent sets of data will be performed using the Pearson correlation coefficient.
While determining the durability of ART is critical in terms of monitoring success and possible ART mutations, the desired outcome is eradication of HIV by 2030.The concept of eradication of the HIV from infected patients has therefore gained much attention in the last few years. ART has changed the dynamic of the HIV epidemic through suppression of HIV-1 RNA to undetectable plasma levels. As a sign of the seriousness of countries to achieve 90-90-90, it is important to track success results at each stage of the HIV continuum of care and most importantly the viral suppression. Although antiretroviral therapy can suppress HIV-1 infection to undetectable levels of plasma viremia, HIV DNA integrate and persist in resting CD4+ T cells. Latent HIV infection of CD4+ T cells, established during the early stages of infection, necessitates lifelong ART, and treatment failure can lead to the selection of drug resistance mutations in the viral genome, which may be archived in the cellular reservoir. Most of the HIV DNA in these cells is defective and cannot cause infection. However, latent HIV-1 genomes that encode replication- competent virus can resurface once ART is discontinued. This latent reservoir having replication- competent virus has a long half-life, and is believed to be the largest impediment to a cure by ART alone. This justifies expansion of research examining HIV latency in the context of sustained viral suppression with an eye towards developing a possible cure regimen that could be used on a large scale. Recently, pharmaceutical approaches have focused on the development of molecules able to reactivate HIV from latently infected cells in order to render them susceptible to combined antiretroviral therapy (c-ART), viral cytopathic effects and host immune responses. Obviously, exposing latent virus and killing it with ART rests on an assumption that the activated virus will be susceptible to the ART a person takes. As such, it is important to discern whether reactivated HIV proviruses are susceptible to the ART regimen for maximum benefit to the patient.
The vast majority of HIV-infected individuals currently live in sub-Saharan Africa where fully suppressive ART is expanding rapidly. Due to this expansion, a large number of patients are expected to achieve full viral suppression. There is need therefore to quantify and document the size of latent HIV reservoir in virally suppressed patients in this region for individualized treatment. To date, there have been no systematic studies to quantify the latent reservoir in virally suppressed HIV-infected patients in Africa. Detecting how much of the inducible virus is left in the human body after antiretroviral therapy poses the greatest challenge to fully curing HIV. Stratifying virally suppressed patients base on the quantity of latent HIV, ART regimens and immune status may inform eligible candidates for latency reactivation care when one comes available.
Hypothesis: Archived proviruses in the latent reservoir are sustained in aviremic patients and are an impediment to HIV cure.
General Objective: Investigate the impact of inducible, replication-competent latent HIV-1 as an impediment to HIV/AIDS cure.
Objectives:
* Document treatment cocktail and determine the rate of viral rebound in aviremic patients; As a sign of the seriousness of countries to achieve 90-90-90, it is important to track success results at each stage of the HIV continuum of care. The investigator will conduct three analyses on patients: 1) Document antiviral cocktail; 2) Duration of viral suppression; 3) Monitor incidences of viral rebound. This will provide a clear framework for using data to maximize linkage, retention and health outcomes. It will also help high-burden countries to use this data at a sub-national and county level to improve service linkage and reduce gaps at each stage of the HIV continuum of care.
* Examine and measure the size of latent HIV reservoirs in virally suppressed patients; Once a patient achieves viral suppression with antiretroviral therapy, it becomes very important to tell how much virus is still left, and whether it can replicate. Such data may lead to an understanding of HIV pathogenesis and to adjust the therapy to improve the quality of life of the HIV patient and inform HIV-1 eradication strategies. This data will enable to identify patients who will be eligible candidates for cure treatment when one comes available.
* Explore the level of immune activation in virally suppressed HIV-infected patients in correlation with the size of the reservoir; In addition to harboring HIV-1 in a long-lived reservoir, individuals on ART have persistently elevated levels of inflammation and T cell activation. Abnormal inflammation and immune activation may contribute to HIV-1 persistence by driving proliferation and activation of HIV-1-infected cells and by activating uninfected cells that can support low-level viral replication. The investigator propose to evaluate sizes of HIV-1 reservoir in relation to inflammation and T cell activation in HIV-1 in aviremic patients on therapy to inform strategies aimed at reducing HIV-1 reservoirs, inflammation and activation that persist despite ART.
Study population: The study will utilize HIV-1 infected patients (18 to 70 years) attending HIV care and treatment facilities in three counties of Meru, Kilifi, and Mombasa. Analysis of medical records to document ART cocktail will be performed. Latent HIV will be determined in patients with viral suppression, defined according to WHO guideline 2016, and followed for 24 months to monitor incidences of viral rebound. A viral load threshold of \<1000 copies/mL defines treatment success according to the 2016 WHO consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Hence subjects with viral load test results below the threshold will be considered as having suppressed viral loads and included in the study. Subjects with complete suppression ( with viral loads below the limit of detection) will also be included in the study.
Study sites: Participants (222) will be recruited from Tudor District Hospital in Mombasa, Malindi District Hospital in Kilifi, Maua Methodist Hospital and Meru Level Five Hospital in Meru Counties of Kenya. Sites were selected depending on volumes of HIV infected individuals registered in the HIV comprehensive care centers who have been taking HAART for at least the last 12 months and have shown virus suppression in at least one of the previous viral load test result.
Sample size calculation: Hospitals will be purposively sampled from each of the three counties of Meru, Kilifi and Mombasa due to the high HIV burden in those counties. Using the reported HIV estimated prevalence in each of the three counties, the sample size will be calculated for each county using the following formula by Armitage. Hence, sample size for;
1. Mombasa County will be; 107 HIV infected individuals
2. Meru County will be; 43 HIV infected individuals
3. Kilifi County will be; 52 HIV infected individuals
Therefore, a minimum sample size of 202 HIV infected individuals will be required for this study. However, to account for potential non-response, non-compliance, and lost to follow-up cases, 10% of the minimum sample size per county will be added hence 222 HIV infected individuals in all the three counties will be utilized.
Ethical consideration: Before commencement of the study, approval will be sought from the Centre for Microbiology Research -KEMRI, Centre Scientific Committee (CSC) as well as the KEMRI Scientific and Ethical Review Unit (SERU). Once the approval is obtained from KEMRI, The investigator will pursue approval for the study from the respective county Director of medical services where the study will be carried out. Thereafter approval from the sites (hospitals) will be sought before commencement of the study. Informed consent will be obtained from adult participants. Recruitment will be voluntary and volunteers will be encouraged to ask questions concerning their rights. Study participants who, during the course of the study are in any way incapacitated will have their consent sought afresh. Participants will not incur any costs as a result of participating in the study and will be free to withdraw from the study whenever they so wish. A coded identification number will be assigned to each participant and used only for the purposes of sample tracking. Documents linking personal identifiers and specimen results will be destroyed after the study. All information will be kept confidential.
Data collection and laboratory methods: Participant sociodemographic data, ART regimen, CD4+ cell count, opportunistic infections, World Health Organization (WHO) staging, and physician-reported adherence will be retrospectively collected from patient folders. All participants will undergo plasma HIV-1 RNA and CD4 quantification at enrollment and after every 6 months during follow up. Baseline viral load and CD4+ cell counts will be closest to ART regimen start. All HIV-1 RNA levels obtained as part of the study, will be made immediately available to the respective physician. The investigator will evaluate every paired HIV-1 viral load (VL) and CD4 count performed to analyze the durability of viral suppression and the risk of rebound among patients with virologic suppression. Time to rebound will be computed using consecutive sequences of observations for subjects whose initial two viral loads will be below the lower limit of quantification and had a viral load measurement within the duration of follow up days.
Statistical analyses: A ratio paired test or equal variance two-sample t-test will be used to calculate the significance while comparing sets of data whenever necessary. All statistical analysis will be performed using PRISM software. A P value of less or equal to 0.05 will be considered to be significant in each of the statistical analyses performed. Correlations between two independent sets of data will be performed using the Pearson correlation coefficient.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
HIV-1-infection
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* • HIV-1 infected patients attending HIV care and treatment facilities in three counties of Meru, Kilifi, and Mombasa.
* Registered at the comprehensive care centre
* Currently prescribed ART
* Able to understand consent process
* Have a viral load threshold of \<1000 copies/mL or with viral loads below the limit of detection
* Registered at the comprehensive care centre
* Currently prescribed ART
* Able to understand consent process
* Have a viral load threshold of \<1000 copies/mL or with viral loads below the limit of detection
Exclusion Criteria
* • High-risk pregnancy for reasons other than HIV status (e.g., pregnancy complications, preeclampia, gestational diabetes, preterm labor)
* Have known history of chronic diseases
* Self-reported participation in another HIV-related study
* Both participant and guardian unable to understand consent process
* Planning on relocating out of study sites over the next 12 months
* Patients of tender years(\<18 yr) or extreme old age (\>70 yr)
* Incapacitated patients will not be recruited
* Have known history of chronic diseases
* Self-reported participation in another HIV-related study
* Both participant and guardian unable to understand consent process
* Planning on relocating out of study sites over the next 12 months
* Patients of tender years(\<18 yr) or extreme old age (\>70 yr)
* Incapacitated patients will not be recruited
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European and Developing Countries Clinical Trials Partnership (EDCTP)
OTHER_GOV
Sponsor Role
collaborator
Kenya Medical Research Institute
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Edward Maina
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Edward K Maina, PhD
Role: PRINCIPAL_INVESTIGATOR
Kenya Medical Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kenya Medical Research Institute
Nairobi, , Kenya
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Kenya
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
NASCOP, "Kenya AIDS Indicator Survey 2012:," Prelim. Rep., 2013.
Reference Type
BACKGROUND
El-Khatib Z, Ekstrom AM, Ledwaba J, Mohapi L, Laher F, Karstaedt A, Charalambous S, Petzold M, Katzenstein D, Morris L. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17;24(11):1679-87. doi: 10.1097/QAD.0b013e32833a097b.
Reference Type
BACKGROUND
Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):500-6. doi: 10.1097/QAI.0b013e3181bcdac1.
Reference Type
BACKGROUND
van Zyl GU, van Mens TE, McIlleron H, Zeier M, Nachega JB, Decloedt E, Malavazzi C, Smith P, Huang Y, van der Merwe L, Gandhi M, Maartens G. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr. 2011 Apr;56(4):333-9. doi: 10.1097/QAI.0b013e31820dc0cc.
Reference Type
BACKGROUND
Dow DE, Shayo AM, Cunningham CK, Reddy EA. Durability of antiretroviral therapy and predictors of virologic failure among perinatally HIV-infected children in Tanzania: a four-year follow-up. BMC Infect Dis. 2014 Nov 7;14:567. doi: 10.1186/s12879-014-0567-3.
Reference Type
BACKGROUND
Inzaule SC, Hamers RL, Mukui I, Were K, Owiti P, Kwaro D, Rinke de Wit TF, Zeh C. Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya. AIDS. 2017 Jun 19;31(10):1495-1498. doi: 10.1097/QAD.0000000000001500.
Reference Type
BACKGROUND
C. Orrell, "Antiretroviral adverse drug reactions and their management:," SA J CPD, vol. 26, no. 9, pp. 234-237, 2011.
Reference Type
BACKGROUND
G. Meintjes, G. Maartens, A. Boulle, F. Conradie, E. Goemaere, and E. Hefer, "Adult antiretroviral therapy guideline.," South Afr J HIV Med, vol. 15, no. 4, pp. 121-143, 2014.
Reference Type
BACKGROUND
Naidoo A, Naidoo K, Yende-Zuma N, Gengiah TN, Padayatchi N, Gray AL, Bamber S, Nair G, Karim SS. Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial. Antivir Ther. 2014;19(2):161-9. doi: 10.3851/IMP2701. Epub 2013 Oct 31.
Reference Type
BACKGROUND
Le T, Wright EJ, Smith DM, He W, Catano G, Okulicz JF, Young JA, Clark RA, Richman DD, Little SJ, Ahuja SK. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013 Jan 17;368(3):218-30. doi: 10.1056/NEJMoa1110187.
Reference Type
BACKGROUND
Dahabieh MS, Battivelli E, Verdin E. Understanding HIV latency: the road to an HIV cure. Annu Rev Med. 2015;66:407-21. doi: 10.1146/annurev-med-092112-152941.
Reference Type
BACKGROUND
Wensing AM, Calvez V, Gunthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD. 2014 Update of the drug resistance mutations in HIV-1. Top Antivir Med. 2014 Jun-Jul;22(3):642-50.
Reference Type
BACKGROUND
PEPFAR, "Kenya Country Operational Plan," 2015.
Reference Type
BACKGROUND
Inzaule S, Otieno J, Kalyango J, Nafisa L, Kabugo C, Nalusiba J, Kwaro D, Zeh C, Karamagi C. Incidence and predictors of first line antiretroviral regimen modification in western Kenya. PLoS One. 2014 Apr 2;9(4):e93106. doi: 10.1371/journal.pone.0093106. eCollection 2014.
Reference Type
BACKGROUND
Gandhi RT, Coombs RW, Chan ES, Bosch RJ, Zheng L, Margolis DM, Read S, Kallungal B, Chang M, Goecker EA, Wiegand A, Kearney M, Jacobson JM, D'Aquila R, Lederman MM, Mellors JW, Eron JJ; AIDS Clinical Trials Group (ACTG) A5244 Team. No effect of raltegravir intensification on viral replication markers in the blood of HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):229-35. doi: 10.1097/QAI.0b013e31823fd1f2.
Reference Type
BACKGROUND
Malnati MS, Scarlatti G, Gatto F, Salvatori F, Cassina G, Rutigliano T, Volpi R, Lusso P. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. Nat Protoc. 2008;3(7):1240-8. doi: 10.1038/nprot.2008.108.
Reference Type
BACKGROUND
Cillo AR, Krishnan A, Mitsuyasu RT, McMahon DK, Li S, Rossi JJ, Zaia JA, Mellors JW. Plasma viremia and cellular HIV-1 DNA persist despite autologous hematopoietic stem cell transplantation for HIV-related lymphoma. J Acquir Immune Defic Syndr. 2013 Aug 1;63(4):438-41. doi: 10.1097/QAI.0b013e31828e6163.
Reference Type
BACKGROUND
Chargin A, Yin F, Song M, Subramaniam S, Knutson G, Patterson BK. Identification and characterization of HIV-1 latent viral reservoirs in peripheral blood. J Clin Microbiol. 2015 Jan;53(1):60-6. doi: 10.1128/JCM.02539-14. Epub 2014 Oct 22.
Reference Type
BACKGROUND
Siliciano JD, Siliciano RF. Enhanced culture assay for detection and quantitation of latently infected, resting CD4+ T-cells carrying replication-competent virus in HIV-1-infected individuals. Methods Mol Biol. 2005;304:3-15. doi: 10.1385/1-59259-907-9:003.
Reference Type
BACKGROUND
Biswas N, Wang T, Ding M, Tumne A, Chen Y, Wang Q, Gupta P. ADAR1 is a novel multi targeted anti-HIV-1 cellular protein. Virology. 2012 Jan 20;422(2):265-77. doi: 10.1016/j.virol.2011.10.024. Epub 2011 Nov 21.
Reference Type
BACKGROUND
Rosenbloom DI, Elliott O, Hill AL, Henrich TJ, Siliciano JM, Siliciano RF. Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1. Open Forum Infect Dis. 2015 Aug 26;2(4):ofv123. doi: 10.1093/ofid/ofv123. eCollection 2015 Dec.
Reference Type
BACKGROUND
Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M Jr, Coffin JM, Mellors JW. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2014 May 13;111(19):7078-83. doi: 10.1073/pnas.1402873111. Epub 2014 Mar 31.
Reference Type
BACKGROUND
Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. AIDS. 2012 May 15;26(8):929-38. doi: 10.1097/QAD.0b013e328351f5b2.
Reference Type
RESULT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SERU Protocol no. 3620
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine
NCT00855413
TERMINATED
PHASE4
Resistance Testing to Improve Management of Virologic Failure in Sub-Saharan Africa
NCT02787499
COMPLETED
NA
Treatment Intensification for HIV Infected Patients With Multi-Drug Resistant Virus
NCT00102934
UNKNOWN
NA
Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression
NCT01034917
COMPLETED
PHASE3
A Long-term Follow-up of the HIV-NAT Cohort
NCT00411983
RECRUITING
Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)
NCT00377065
APPROVED_FOR_MARKETING
Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
NCT00532168
COMPLETED
PHASE4
ACE Inhibitors to Decrease Lymphoid Fibrosis in Antiretroviral-Treated, HIV-infected Patients: A Pilot Study
NCT01535235
COMPLETED
PHASE4
Efficacy and Tolerance of the Switch From Enfuvirtine to Raltegravir in Antiretroviral Therapy Regimen in HIV Patients With Undetectable Viral Load
NCT00454337
COMPLETED
PHASE3
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
NCT07053384
RECRUITING
PHASE1
A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments
NCT06337032
RECRUITING
PHASE4
Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.
NCT00460746
COMPLETED
PHASE3
Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients
NCT02384967
COMPLETED
PHASE2
A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells
NCT01173510
WITHDRAWN
PHASE4
Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia
NCT03198325
COMPLETED
NA
Optimizing Treatment for Treatment-Experienced, HIV-Infected People
NCT00537394
COMPLETED
PHASE3
Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection
NCT02219672
UNKNOWN
PHASE3
Effectiveness of Antiretroviral Therapy During Acute HIV Infection
NCT00705926
COMPLETED
PHASE1
Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)
NCT03859739
COMPLETED
PHASE1
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
NCT01440569
COMPLETED
PHASE3
Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia
NCT00618371
COMPLETED
NA
The Neurocognitive Sub-study of Encore1
NCT01516060
COMPLETED
PHASE3
Research In Viral Eradication of HIV Reservoirs
NCT02336074
COMPLETED
PHASE2
Effect on HIV Medications on EPC Cells
NCT03782142
COMPLETED